Tag:

Oncothyreon

Latest Headlines

Latest Headlines

Oncothyreon sells drug rights, cuts jobs

FierceBiotech | December 19, 2008
Merck KgAA is paying $13 million for manufacturing rights to Oncothyreon's experimental lung cancer vaccine Stimuvax. Merck already owns the commercialization and development rights to the lung
Related Tags

Oncothyreon Press Releases

  • Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
  • Oncothyreon Prices $40.0 Million Public Offering of Common Stock
  • Oncothyreon Appoints Guy Cipriani as Vice President, Business Development
Press Releases
  • U.S. FDA Panel Supports Medtronic, Inc. (MDT) Pacemaker
  • Atritech, Inc. Announces FDA Regulatory Update; Confirmatory Study Required for Final FDA Approval
  • FDA APPROVES FIRST OF ITS KIND, FULLY IMPLANTABLE (SURGICALLY), INVISIBLE, PROSTHETIC HEARING RESTORATION DEVICE
  • CryoLife Comments on Status of Medafor Distribution Agreement
  • FDA Statement on Boston Scientific Recall of Implantable Cardioverter Defibrillators
  • More Press Releases
Featured Jobs
  • Project Manager - Regulatory Affairs
    Wockhardt -
  • VICE PRESIDENT, CLINICAL RESEARCH
    Soligenix, Inc. - Princeton NJ USA
  • SAS Programming - All levels
    Theorem Clinical Research - United States and Canada
  • Vice President, Global Medical Affairs - Multiple Myeloma Job
    Celgene Corporation - Summit NJ US
  • Senior Scientist III, Oncology - 1300000444
    Abbvie - Chicago IL United States
Sponsored Links